Saturday 17 October 2026
Export CLGN’s income statement to Excel — free account
CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
3.60
0.08
−2.17%
Follow CLGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.83 | 7.21 | 18.94 | 15.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.90) | (5.82) | (2.42) | (2.16) | |
P/B ratio |
3.68 | 2.81 | 1.51 | 1.71 | |
Price to Tangible BV |
3.71 | 2.84 | 1.53 | 1.74 | |
EV/Sales |
12.46 | 7.00 | 21.07 | 23.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.10) | (1.76) | (0.73) | (0.67) | |
EV/FCF |
(3.07) | (1.75) | (0.72) | (0.67) | |
Quick Ratio |
3.45 | 2.31 | 1.99 | 1.35 | |
Current Ratio |
3.66 | 2.53 | 2.27 | 1.57 | |
Net Debt/EBITDA |
2.69 | 2.03 | 1.59 | 1.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.16 | 0.03 | 0.03 | |
Operating CF/Net income |
0.83 | 0.92 | 0.98 | 0.86 | |
Capex/Depreciation |
0.00 | (0.07) | (0.03) | 0.07 | |
Interest Coverage |
— | — | — | (28.31) | |
Research and Development Expense of Revenue |
2,712.99% | 3,300.00% | 2,298.63% | 1,078.70% | |
Selling, General and Administrative Expense of Revenue |
1,592.21% | 1,730.00% | 1,635.62% | 937.04% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
366.23% | (30.00%) | 246.58% | 152.78% | |
Graham Net Nets |
0.14 | 0.12 | 0.17 | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(37.92%) | (67.02%) | (193.71%) | (271.40%) | |
Free Cash Flow Yield |
(29.40%) | (55.54%) | (154.28%) | (223.27%) | |
Revenue per Share |
0.06 | 0.05 | 0.05 | 0.07 | |
Operating CF per Share |
(2.26) | (2.41) | (2.22) | (1.62) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.01 | |
Free Cash Flow per Share |
(2.26) | (2.42) | (2.22) | (1.61) | |
Cash per Share |
6.94 | 4.88 | 3.37 | 2.05 | |
Shareholders Equity per Share |
7.31 | 4.98 | 3.55 | 2.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.31 | 4.98 | 3.55 | 2.04 | |
Free Cash Flow |
(2.88) | (2.95) | (3.05) | (2.32) | |
Working Capital |
6.99 | 4.08 | 3.10 | 1.41 | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | 0.01 | |
Net Current Asset Value |
4.84 | 2.04 | 1.24 | (0.36) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.25 | 0.08 | (0.13) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.34 | 0.40 | 0.34 | 0.38 | |
Average Payables |
0.81 | 0.74 | 0.70 | 0.41 | |
Average Inventory |
0.50 | 0.51 | 0.68 | 0.55 | |
Average Assets |
18.27 | 14.75 | 13.20 | 12.32 | |
Average Common Equity |
13.11 | 9.77 | 8.64 | 7.73 |
Columns are period end dates · fundamentals updated 6 Oct 2026